Filtered By:
Cancer: Cancer
Nutrition: Milk

This page shows you your search results in order of date.

Order by Relevance | Date

Total 22 results found since Jan 2013.

High consumption of dairy products and risk of major adverse coronary events and stroke in a Swedish population
Br J Nutr. 2023 Sep 6:1-28. doi: 10.1017/S0007114523001939. Online ahead of print.ABSTRACTThe association between consumption of dairy products and risk of cardiovascular diseases (CVD) has been inconsistent. There is a lack of studies in populations with high intakes of dairy products. We aimed to examine the association between intake of dairy products and risk of incident major adverse coronary events and stroke in the Swedish Malmö Diet and Cancer cohort study. We included 26,190 participants without prevalent CVD or diabetes. Dietary habits were obtained from a modified diet history and endpoint data were extracted f...
Source: The British Journal of Nutrition - September 6, 2023 Category: Nutrition Authors: Justine Dukuzimana Suzanne Janzi Caroline Habberstad Shunming Zhang Yan Born é Emily Sonestedt Source Type: research

Too Little Sleep Destroys DNA?
I talk to my patients about the danger of not sleeping all the time. Unfortunately, it’s a common problem that affects 75 million Americans. People who don’t sleep, or sleep poorly, have up to 400% more accidents that those who get a good night’s rest. Not getting enough sleep also increases your risk of developing chronic diseases. Studies, including a large meta-analysis of 470,000 adults, found that those who slept less than six hours developed a:1,2,3,4,5 48% increase in the incidence of coronary heart disease 30% increased risk of dementia 15% increase in the incidence of stroke 50% cancer risk 17% higher risk ...
Source: Al Sears, MD Natural Remedies - August 25, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Health Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Stroke, Dietary Fish, Milk, and Sugar Consumption Correlates of Alzheimer's and Parkinson's Dementia
To investigate the potentially confounding factors in the relationship between daily sugar intake versus Alzheimer& Parkinson's related death rates, including milk, meat, fish and alcohol consumption; obesity, stroke, hypertension, cancer and diabetes rates; tobacco use; and gross domestic purchasing power parity in different countries.
Source: Archives of Physical Medicine and Rehabilitation - December 1, 2022 Category: Rehabilitation Authors: Kurt Gold, Jacob Galloway, Justin Schwartz, Jonathan Huefner, Elizabeth Call, Taoyuan Beninato, Gabriela Garaycochea, Ronald Bulbulian Tags: Research Poster 2184247 Source Type: research

Drinking Black Tea May Lower Mortality Risk, Study Suggests
While green tea has a long-standing reputation for health benefits, research has been much more mixed on black tea. One problem, says Maki Inoue-Choi, an epidemiologist at the National Cancer Institute, is that large observational studies on tea and mortality have focused on countries like Japan or China—places where green tea is more popular. To fill this gap, Inoue-Choi and her colleagues analyzed data in the United Kingdom, where black tea drinking is common. After surveying about 500,000 people and following them for a median of 11 years, the results, published Aug. 29 in the journal Annals of Internal Medicine, ...
Source: TIME: Health - August 29, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized Diet & Nutrition healthscienceclimate Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Featured Review: Taxation of the fat content of foods for reducing their consumption and preventing obesity or other adverse health outcomes
ConclusionsWe did not find enough reliable evidence to find out whether a tax on the fat content of foods resulted in people eating less fat, or less saturated fat.We did not find any evidence about how a tax on the fat content of foods affected obesity or overweight.The results of our review will change when further evidence becomes available.Discussing the findings of this review, lead author Stefan Lhachimi said, “A tax on saturated fats could be in principle a good approach to reduce the consumption of so-called junk foods, a group of food products which is fiendishly tricky to define in legal terms. By taxing a main...
Source: Cochrane News and Events - September 7, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news

Study: Drinking Tea May Help You Live Longer, Especially If It ’ s Green
This study strengthens the body of evidence that habitual tea drinking is associated with lower rates of atherosclerotic cardiovascular disease, though it cannot prove that it’s definitely the tea that’s responsible,” Dr. Jenna Macciochi, a lecturer in immunology at the University of Sussex, told the SMC. However, she noted that “a body of evidence in nutrition suggests that whole diet patterns are more informative of diet-disease relationships than any isolated food or nutrient.” Dr. Duane Mellor, a registered dietitian and senior teaching fellow at Aston Medical School, Aston University, sai...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 10, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Green Tea Source Type: news

Cryptotanshinone Attenuates Oxygen-Glucose Deprivation/ Recovery-Induced Injury in an in vitro Model of Neurovascular Unit
Conclusions Despite the above limitations, we indicate that the protective mechanism of CTs against OGD/R damage might exert via inhibiting neuron apoptosis and attenuating BBB disruption. Furthermore, we also clarified that CTs inhibited neuronal apoptosis possibly by blocking the activation of MAPK signaling pathways, and CTs alleviating BBB disruption may associated with the regulation of TJPs and MMP-9 in our experiment. Accordingly, CTs will represent a novel and potent candidate for the treatment of CIRI in the future. Ethics Statement This study was carried out in accordance with the recommendations of China�...
Source: Frontiers in Neurology - April 17, 2019 Category: Neurology Source Type: research

C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
Conclusions: This meta-analysis revealed that PD is associated with an increase of CRP levels. CRP might be a risk factor for PD or PD leads to an inflammatory response. Introduction Parkinson's disease (PD) is one of the most complex neuro-degenerative disorders next to Alzheimer's disease. It is characterized by bradykinesia, tremor, rigidity, abnormal postural, and gait (1). PD has been recognized by the selective loss of dopaminergic neurons within the substantia nigra pars compacta, whereas the exact etiology remains elusive (2). Previously, multiple inferences have reviewed the environmental a...
Source: Frontiers in Neurology - April 16, 2019 Category: Neurology Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

The Effects of Intelectin-1 on Antioxidant and Angiogenesis in HUVECs Exposed to Oxygen Glucose Deprivation
Conclusion: These results suggest intelectin-1 promotes angiogenesis, inhibits oxidative stress and reduces apoptosis by stimulating the Akt-eNOS signaling pathway in response to ischemia in vitro. Introduction Stroke is a main reason of human neurological disability, ischemic stroke (IS) accounts for almost 80–90% of all strokes. IS occurs after a cerebral blood flow disruption, leading to cellular death and tissue damage by restricting glucose and oxygen supplies (1). Ischemic vascular diseases cause substantial vascular valve and vascular endothelial cell injuries, eventually damaging the surrounding tis...
Source: Frontiers in Neurology - April 15, 2019 Category: Neurology Source Type: research